VET3-TGI
Advanced Solid Tumors
Phase 1Active
Key Facts
About KaliVir Immunotherapeutics
KaliVir Immunotherapeutics is a private, Pittsburgh-based biotech founded in 2019, focused on engineering novel oncolytic viruses to treat cancer. Its proprietary VET platform aims to overcome limitations of earlier oncolytic viruses by enhancing tumor selectivity, immune activation, and the ability to deliver therapeutic payloads. The company has assembled a seasoned leadership team with deep experience in oncolytic virus development and has secured a significant partnership with Roche for its lead candidate, positioning it as a notable player in the next wave of cancer immunotherapy.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |